i think it's a bit of a "tomato, tomato" thing for me there. Pros and cons to both if you watch the videos with clinicians discussing it. Overall, they're indifferent about it, which says it's not much of a differentiator.
Ann: First patient imaged in Phase III AMPLIFY trial, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.28 |
Change
0.050(2.24%) |
Mkt cap ! $739.1M | |||
| Open | High | Low | Value | Volume |
| $2.30 | $2.37 | $2.21 | $5.126M | 2.230M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 6604 | $2.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.28 | 3987 | 8 |
View Market Depth
| Last trade - 14.29pm 17/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |